{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:29:44Z","timestamp":1791041384021,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,1,15]]},"abstract":"<jats:p>PURPOSE: This phase I clinical trial was designed to determine the maximum-tolerated dose and dose-limiting toxicities of the matrix metalloproteinase (MMP) inhibitor COL-3 in patients with refractory solid tumors.<\/jats:p><jats:p>PATIENTS AND METHODS: Thirty-five patients with different cancer types were enrolled. COL-3 doses were escalated from 36 mg\/m<jats:sup>2<\/jats:sup>\/d in successive cohorts of at least three patients. Circulating levels of MMP-2, MMP-9, vascular endothelial growth factor, and basic fibroblast growth factor were assessed during treatment. Pharmacokinetic parameters were assessed for single and multiple doses of drug.<\/jats:p><jats:p>RESULTS: Cutaneous phototoxicity was dose-limiting at 98 mg\/m<jats:sup>2<\/jats:sup>\/d. With the use of prophylactic sunblock, COL-3 was well tolerated at 70 mg\/m<jats:sup>2<\/jats:sup>\/d. The dose of 36 mg\/m<jats:sup>2<\/jats:sup>\/d was well tolerated without the use of sunblock. Other toxicities that did not seem to be related to dose or pharmacokinetics included anemia, anorexia, constipation, dizziness, elevated liver function test results, fever, headache, heartburn, nausea, vomiting, peripheral and central neurotoxicities, fatigue, and three cases of drug-induced lupus. Disease stabilization for periods of 26+ months, 8 months, and 6 months were seen in hemangioendothelioma, Sertoli-Leydig cell tumor, and fibrosarcoma, respectively. There was a potentially statistically significant relationship between changes in plasma MMP-2 levels and cumulative doses of drug when progressive disease patients were compared with those with stable disease or toxicity (P = .042).<\/jats:p><jats:p>CONCLUSION: COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy. Phototoxicity was dose-limiting. We recommend the dose of 36 mg\/m<jats:sup>2<\/jats:sup>\/d for phase II trials.<\/jats:p>","DOI":"10.1200\/jco.2001.19.2.584","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:36:55Z","timestamp":1487921815000},"page":"584-592","source":"Crossref","is-referenced-by-count":118,"title":["Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer"],"prefix":"10.1200","volume":"19","author":[{"given":"Michelle A.","family":"Rudek","sequence":"first","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Dyer","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Dahut","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Turner","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Liewehr","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Kohler","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Pluda","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Reed","sequence":"additional","affiliation":[{"name":"From the Medicine Branch, Division of Clinical Sciences; Biostatistics and Data Management Section; Investigational Drug Branch, Cancer Therapy Evaluation Program; and Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-083520","unstructured":"Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99,1990-106,"},{"key":"R2-083520","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.17.1260"},{"key":"R3-083520","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0765.1983.tb00388.x"},{"key":"R4-083520","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0765.1984.tb01334.x"},{"key":"R5-083520","doi-asserted-by":"crossref","unstructured":"Golub LM, Goodson JM, Lee HM, et al: Tetracyclines inhibit tissue collagenases: Effects of ingested low-dose and local delivery systems. J Periodontol 56: 93,1985-97,","DOI":"10.1902\/jop.1985.56.11s.93"},{"key":"R6-083520","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0765.1985.tb00405.x"},{"key":"R7-083520","doi-asserted-by":"publisher","DOI":"10.1177\/10454411910020030201"},{"key":"R8-083520","doi-asserted-by":"publisher","DOI":"10.1177\/08959374980120010301"},{"key":"R9-083520","doi-asserted-by":"crossref","unstructured":"Ramamurthy NS, Vernillo AT, Greenwald RA, et al: Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res 8: 1247,1993-1253,","DOI":"10.1002\/jbmr.5650081013"},{"key":"R10-083520","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1994.tb24778.x"},{"key":"R11-083520","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390209"},{"key":"R12-083520","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006588708131"},{"key":"R13-083520","doi-asserted-by":"publisher","DOI":"10.1177\/08959374980120012701"},{"key":"R14-083520","doi-asserted-by":"publisher","DOI":"10.1177\/08959374980120012901"},{"key":"R15-083520","unstructured":"Pruzanski W, Stefanski E, Vadas P, et al: Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2. J Rheumatol 25: 1807,1998-1812,"},{"key":"R16-083520","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.1787"},{"key":"R17-083520","doi-asserted-by":"publisher","DOI":"10.1177\/08959374980120010901"},{"key":"R18-083520","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(00)00257-0"},{"key":"R20-083520","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.15.1138"},{"key":"R22-083520","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512283332608"},{"key":"R23-083520","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1993.tb02242.x"},{"key":"R24-083520","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600660213"},{"key":"R25-083520","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12263531"},{"key":"R26-083520","doi-asserted-by":"publisher","DOI":"10.1016\/S1011-1344(98)00104-3"},{"key":"R27-083520","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890460044005"},{"key":"R28-083520","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1965.tb00085.x"},{"key":"R29-083520","unstructured":"Saidi P, Wallerstein RO, Aggeler PM: Effect of chloramphenicol on erythropoiesis. J Lab Clin Med 57: 247,1961-256,"},{"key":"R30-083520","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1965.tb00088.x"},{"key":"R31-083520","doi-asserted-by":"crossref","unstructured":"Bowman WD: Abnormal (\u201cringed\u201d) sideroblasts in various hematologic and non-hematologic disorders. Blood 18: 662,1962-671,","DOI":"10.1182\/blood.V18.6.662.662"},{"key":"R32-083520","unstructured":"Campistron G, Coulais Y, Caillard C, et al: Pharmacokinetics and bioavailability of doxycycline in humans. Arzneimittelforschung 36: 1705,1986-1707,"},{"key":"R33-083520","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.3.462"},{"key":"R34-083520","unstructured":"Wojcicki J, Kalinowski W, Gawronska-Szklarz B: Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia. Arzneimittelforschung 35: 991,1985-993,"},{"key":"R35-083520","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM195811202592102"},{"key":"R36-083520","doi-asserted-by":"publisher","DOI":"10.1177\/096032718800700306"},{"key":"R37-083520","unstructured":"Seitz C, Garcia P, Arancibia A: Influence of ethanol ingestion on tetracycline kinetics. Int J Clin Pharmacol Ther 33: 462,1995-464,"},{"key":"R38-083520","doi-asserted-by":"publisher","DOI":"10.1159\/000238345"},{"key":"R39-083520","doi-asserted-by":"crossref","unstructured":"Bernard B, Yin EJ, Simon HJ: Clinical pharmacologic studies with minocycline. J Clin Pharmacol New Drugs 11: 332,1971-348,","DOI":"10.1177\/009127007101100504"},{"key":"R40-083520","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1969105690"},{"key":"R41-083520","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-110-27501"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.2.584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:30:04Z","timestamp":1692700204000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.2.584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,15]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,1,15]]}},"alternative-id":["10.1200\/JCO.2001.19.2.584"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.2.584","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,15]]}}}